Blog Archive

Archive for: February
PLS-Design researchers and academic partners will present at the German Society for Allergology and Clinical Immunology (DAGKI) 25th Allergy-Workshop in Mainz (Germany) on 7th of March 2013.
See here for more information about the jubilee meeting.
The complete program can be found here.
Session 1
Key note : Molekulare Allergiediagnostik – ein echter Mehrwert für die klinische Allergologie
(Molecular allergy diagnostics – a true additional value for clinical allergology)
Prof. M. Ollert

Session 3
V20: IgE reactivity to a broad panel of CCD free bee venom allergens reveals diverse sensitisation profiles in bee venom allergic patients
Julian Köhler, S. Blank , S. Müller, F. Bantleon, J. Huss-Marp, J. Lidholm, E. Spillner, T. Jakob

V21: Polistes species venom is devoid of carbohydrate-based cross-reactivity and allows interference-free diagnostics
Simon Blank, C. Neu, D. Hasche, F. Bantleon, T. Jakob, E. Spillner

V22: Fine specificity of IgE and IgG carbohydrate reactivity dissected by establishing xenobiotic epitopes with glycoengineered cells
Frank Bantleon, S. Blank, M. Plum, T. Jakob, E. Spillner

V23: Structural and functional insights into the high affinity recognition of xenobiotic N-glycan core modifications by monoclonal antibodies from rabbit immune repertoires
Melanie Plum, F. Bantleon, M. Kötzler, J. Eckenberger, S. Wolf, S. Blank, A. Diethers, B. Meyer, E. Spillner

27 Feb 2013

Omalizumab for urticaria study status

By There are no tags 0 comments

In the online edition of the “New England Journal of Medicine” the first results from the Novartis Phase III study (ASTERIA II) of the use of omalizumab for chronic sponaneous urticaria (CSU) have been published. The data were also presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in San Antonio, Texas, USA.
Novartis claims that the results indicate that Omalizumab is a potentially valuable treatment option for moderate to severe refractory chronic idiopathic or spontaneous urticaria (CIU/CSU). Novartis aims at a regulatory submission for this new application of Omalizumab in 2013.

See NEJM site for article:
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Maurer M, Rosén K, Hsieh H-J, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, and Casale T.

See Novartis press release here.

IgE-Quantification can be used to monitor an anti-IgE therapy, like omalizumab treatment.
For example, the amount of remaining free IgE under omalizumab treatment can be quantified using PLS-Design‘s IgE-AviQuant molecule. Read more here!

From time to time PLS-Design will post references of peer-reviewed articles, which we find highly interesting for our field of activities.

This time we would like to point to two articles from the February issue of “Nature Immunology”. The articles show that the technology of PLS-Design to interfere with complement to modulate regulatory T cells is a hot topic (…who would have guessed that).

See also our page for PLS-Design‘s technology of complement interference.
For more information, please feel free to contact us (

23 Feb 2013

Welcome to our new web site

By There are no tags 0 comments

Hello World,

Welcome to PLS-Design’s new web site. To level with our R&D standards we deployed this improved web site.

This web site will allow closer communication with our customer and research partners, as well as providing hopefully interesting information to all others. We envision to extent this site to a preferred place of information and reference about immune system modulation, because – that is our Business!

PLS-Design joined the social cloud. You can now reach PLS in Twitter, Facebook and Google+…more to come.

We do hope you like our site and stay with us for a while. We will do our best to make it a pleasent stay – promised!

PLS-Design Admin

Copyright 2018 by PLS-Design GmbH